Abstract
Doxorubicin (Adriamycin) is an anthracycline chemotherapy agent used for the treatment of several cancers including haematological malignancies. Extravasation is a well-recognized and possibly serious complication of administered intravenous therapies, especially in chemotherapeutic agents. Drug extravasation into the surrounding tissue has been estimated to occur in 0.1–6% of patients that receive chemotherapy. Signs of the injury can be subtle, and in case of delayed detection (> 6 h) and treatment, doxorubicin extravasation can result in substantial tissue damage with significant loss of function depending on the location of injury. Other consequences include pain, physical defect, psychological distress, cost of hospitalization and treatment and more extensive damage to skin and underlying tissue. In this article, we will discuss a case of delayed treatment of doxorubicin extravasation from a Venflon venous line at the dorsum of the hand with severe tissue necrosis as a result. Successful surgical reconstruction of the resulting substantial tissue damage using a SCIAP flap 25 days following the extravasation is described. Level of evidence: Level V, risk study.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
